Celgene Corporation (NASDAQ:CELG) was in the news a few months ago for buying Abraxis BioScience for 2.9 billion (read: A Billionaire’s Biotech Deal And Old Drugs Reborn at forbes.com, or Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion at nytimes.com) With this purchase, Celgene has become a big player in the Oncology biz-space with two re-incarnated drugs:
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label bortezomib. Show all posts
Showing posts with label bortezomib. Show all posts
Wednesday, October 13, 2010
Subscribe to:
Posts (Atom)